ITI 214

Drug Profile

ITI 214

Alternative Names: IC-200214; ITI-214

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intra-Cellular Therapies
  • Class Antiparkinsonians; Nootropics; Small molecules
  • Mechanism of Action Type 1 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Parkinson's disease
  • Phase I Cognition disorders

Most Recent Events

  • 01 Sep 2017 Phase-I/II clinical trials in Parkinson's disease in USA (PO) (NCT03257046)
  • 06 Mar 2017 ITI 214 is still in phase I trials for Cognition disorders in USA and Japan
  • 01 Mar 2017 Intra-Cellular Therapies plans a phase I/II trial in Parkinson's disease in USA (PO) (NCT03257046)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top